“Wisdom” and “M42” expect a strategic memorandum of understanding to enhance innovation in the field of health care

The company “Hikma Varmasiotics B.C.” has announced. (“Wisdom” or “Group”), the group of multinationals, today, signing a strategic memorandum of understanding with “M42”, the world leader in the field of health care, supported by artificial intelligence (AI) and technology. The Memorandum of Understanding, which was signed on The margin of the “Arab Health Exhibition and Conference 2025”, to enhance innovation in the field of health care in the UAE, by accelerating the implementation of the most accurate and preventive cancer care programs, using advanced genomic examination technology. Through the agreement, the “wisdom” and the “M42” company established their cooperation to enhance the use of SHIELD ™, which is the first non -interventional test based on blood known as liquid biopsy, accredited by the American Food and Drug Administration produced by Guardant Health Inc. To detect colon and rectal cancer, with the aim of improving the rates of commitment to examination in the UAE and giving patients a greater opportunity for early detection and immediate intervention. The SHIELD ™ test forms a preliminary option to examine colon and rectal cancer, allows health care providers to present it to patients just like any other recommended examination in Examination instructions. The Abu Dhabi Public Health Center, in partnership with M42, recently launched a SHIELD ™ blood test for early detection of colon and rectum cancer, as part of the comprehensive health examination program “Check”. SHIELD ™ was provided for a examination in the main M42 health centers throughout Abu Dhabi, Al Ain and Al Dhafra. This, Mazen Darouza, Vice Chairman and Chairman of the Middle East and North Africa region at Al -Hikma said: “We are proud to sign a strategic partnership with“ M42 ”, In the context of our commitment and our common vision of innovation, to enhance the future of health care and improve patient results. This important step focuses on enhancing early detection of diseases, enabling diagnostic processes more accurately, and ensuring the arrival of the most effective treatments, especially in the areas of oncology and preventive care, in line with Our ambition of providing health care solutions based on careful and specialized medicine. ”On his part, Dr. Fahd Al Marzouki, CEO of the platform of integrated health solutions at 2M4 said:“ We adhere to “M42” to exploit the latest technology to improve patient results and enable care systems Health is to provide proactive care. Cooperation with “wisdom” reflects our efforts to support Abu Dhabi’s efforts to consolidate innovation in the health care sector. “Wisdom” last year on the signing of an exclusive agreement with Guardant Health to market its product portfolio from liquid samples tests, tissue tests for cancer examination, monitoring its repetition, and stereotyping oncology mutations, for all types of solid cancers in the Middle East and North Africa. The agreement includes several tests such as the SHIELD ™ test, for early detection of colon and rectal cancer, the Guardant Reveal ™ test to detect the minimum remaining disease and monitor the repetition of infection, the Guardant360 and ™ Guardant360 Tissuenext for comprehensive genomic formation of all types of solid cancer tissue. D ™ for early detection of colon and rectal cancer is an important positive step towards developing accurate and preventive health care systems throughout the region.